Regenerative medicine holds extraordinary promise for transforming the treatment of chronic and life-threatening diseases. Yet the field continues to advance on an incomplete scientific foundation: the underrepresentation of women and non-binary people in both preclinical and clinical research. This is not a minor oversight, but a fundamental limitation that compromises the safety, accuracy and translational
